| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
CECR2 30 nM (IC50) CECR2 10 nM (Kd) CECR2 7.5 (pIC50) BPTF 350 nM (IC50) BPTF 120 nM (Kd) BPTF 6.5 (pIC50) BRD9 5.9 (pIC50)
The primary biological targets of TP-238 are the bromodomains of CECR2 (cat eye syndrome chromosome region, candidate 2) and BPTF (bromodomain PHD finger transcription factor). Bromodomains are epigenetic reader modules that recognize acetylated lysine residues on histone tails and regulate gene transcription. CECR2 is a component of the CERF (CECR2-containing remodeling factor) chromatin remodeling complex, which is involved in transcriptional regulation. BPTF is a subunit of the NURF (nucleosome remodeling factor) complex. By binding to these bromodomains, TP-238 displaces them from chromatin, thereby modulating gene expression. It also inhibits BRD9 with lower potency. |
|---|---|
| ln Vitro |
TP-238 has metabolic activity that is on target at 10–30 nM for CECR2 and 100–350 nM for BPTF. TP-238 shows efficacy in an Alpha screen assay for both BPTF (pIC50 of 6.5) and CECR2 (pIC50 of 7.5). With a Kd of 10 nM for CECR2 and 120 nM for BPTF, isothermal titration calorimetry (ITC) reveals TP-238[1][2].
In vitro, TP-238 has on-target biochemical activity of 10-30 nM with CECR2 and 100-350 nM with BPTF. It displays potency for both CECR2 (pIC50 of 7.5) and BPTF (pIC50 of 6.5) in an Alpha screen assay. Isothermal titration calorimetry (ITC) shows TP-238 with a Kd of 10 nM for CECR2 and 120 nM for BPTF. It also inhibits BRD9 with a pIC50 of 5.9. The compound is a valuable tool for studying the biological functions of CECR2 and BPTF in cellular processes such as transcription, chromatin remodeling, and development. |
| ln Vivo |
In vivo, TP-238 has been used in a mouse model of a developmental disorder. In this model, the compound is administered at a dose of 10 mg/kg via intraperitoneal (IP) injection once daily for 14 days. Behavioral testing is conducted 1 hour after the final injection. This study demonstrates the compound's ability to modulate CECR2 and BPTF activity in vivo. Further studies are needed to characterize its pharmacokinetic properties and its efficacy in other disease models. Its high potency and selectivity make it a valuable probe for in vivo studies.
|
| Enzyme Assay |
The non-cellular enzyme or receptor binding assay for TP-238 involves measuring its binding affinity to the bromodomains of CECR2 and BPTF. This can be performed using a time-resolved fluorescence resonance energy transfer (TR-FRET) or Alpha screen assay. In a typical Alpha screen assay, a biotinylated acetyl-lysine peptide probe is incubated with the bromodomain protein and streptavidin-coated donor beads. The binding of the protein to the peptide brings the donor and acceptor beads into proximity, generating a signal. TP-238 competes for the acetyl-lysine binding site, displacing the probe and reducing the signal. The IC50 values are determined from the dose-response curves.
|
| Cell Assay |
The in vitro cellular assay for TP-238 involves treating cells with various concentrations of the compound. The effect on CECR2 and BPTF bromodomain-dependent gene transcription is assessed by measuring the expression of target genes using quantitative RT-PCR. The compound's cellular activity can also be assessed using a reporter gene assay. In primary neuronal cultures, TP-238 is used to assess its effect on the phosphorylation status of specific proteins. The compound's selectivity is confirmed by profiling against a panel of other bromodomains and kinases. These assays are used to characterize the cellular effects of CECR2 and BPTF inhibition.
|
| Animal Protocol |
The in vivo animal experiment workflow for TP-238 involves a mouse model of a developmental disorder. The compound is administered at a dose of 10 mg/kg via intraperitoneal (IP) injection once daily for 14 days. Behavioral testing is conducted 1 hour after the final injection to assess the effect of the compound on the disorder. The compound's concentration in the brain and plasma can be measured using LC-MS/MS. Further studies are needed to determine its efficacy in other animal models and to characterize its pharmacokinetic properties.
|
| References |
| Molecular Formula |
C22H30N6O3S
|
|---|---|
| Molecular Weight |
458.58
|
| Exact Mass |
458.21
|
| CAS # |
2415263-04-4
|
| Related CAS # |
TP-238 hydrochloride;2415263-05-5
|
| PubChem CID |
137796292
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
2.4
|
| tPSA |
111
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
32
|
| Complexity |
636
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN(C)CCCOC1=CC=C(C=C1)C2=CC(=NC(=N2)S(=O)(=O)C)NCCCN3C=CC=N3
|
| InChi Key |
MSIJJXOWLFOYIN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H30N6O3S/c1-27(2)13-6-16-31-19-9-7-18(8-10-19)20-17-21(26-22(25-20)32(3,29)30)23-11-4-14-28-15-5-12-24-28/h5,7-10,12,15,17H,4,6,11,13-14,16H2,1-3H3,(H,23,25,26)
|
| Chemical Name |
6-[4-[3-(dimethylamino)propoxy]phenyl]-2-methylsulfonyl-N-(3-pyrazol-1-ylpropyl)pyrimidin-4-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1806 mL | 10.9032 mL | 21.8064 mL | |
| 5 mM | 0.4361 mL | 2.1806 mL | 4.3613 mL | |
| 10 mM | 0.2181 mL | 1.0903 mL | 2.1806 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.